Prophylaxis vs. on-demand treatment with BAY 81-8973 a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II)

摘要

BackgroundBAY 81-8973 is a new full-length human recombinant factor VIII product manufactured with technologies to improve consistency in glycosylation and expression to optimize clinical performance.